Inventor
HAZEN STANLEY L
US46 patents
⚠️ This page may combine multiple inventors who share the name “HAZEN STANLEY L”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CLEVELAND CLINIC FOUND
19 patentsUS10933072B2Mar 2, 2021
Treating and preventing disease with TMA and TMAO lowering agents
CLEVELAND CLINIC FOUND4 citations84
US9694020B2Jul 4, 2017
Treating and preventing disease with TMA and TMAO lowering agents
CLEVELAND CLINIC FOUND8 citations84
US11911399B2Feb 27, 2024
Treating and preventing disease with TMA and TMAO lowering agents
CLEVELAND CLINIC FOUND1 citations73
US10117879B2Nov 6, 2018
Treating and preventing disease with TMA and TMAO lowering agents
CLEVELAND CLINIC FOUND3 citations73
US10983100B2Apr 20, 2021
Trimethylamine-containing compounds for diagnosis and prediction of disease
CLEVELAND CLINIC FOUND3 citations71
US10551372B2Feb 4, 2020
Trimethylamine compounds as risk predictors of cardiovascular disease
CLEVELAND CLINIC FOUND2 citations71
US12092648B2Sep 17, 2024
Detection of glucuronidated and 3-bromotyrosine
CLEVELAND CLINIC FOUND0 citations62
US11249091B2Feb 15, 2022
Detection of glucuronidated and 3-bromotyrosine
CLEVELAND CLINIC FOUND0 citations62
US12055535B2Aug 6, 2024
Trimethylamine compounds as risk predictors of cardiovascular disease
CLEVELAND CLINIC FOUND0 citations61
US12576055B2Mar 17, 2026
Disease detection and treatment based on trimethyl-lysine levels
CLEVELAND CLINIC FOUND0 citations55
US12292451B2May 6, 2025
ApoA1 exchange rate assays in serum
CLEVELAND CLINIC FOUND0 citations55
US11771659B2Oct 3, 2023
Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway
CLEVELAND CLINIC FOUND1 citations53
US9612242B2Apr 4, 2017
Combined F2-isoprostane and myleoperoxidase detection, a risk indicator for cardiovascular disease
CLEVELAND CLINIC FOUND0 citations51
US9581597B2Feb 28, 2017
Myeloperoxidase, a risk indicator for cardiovascular disease
CLEVELAND CLINIC FOUND0 citations51
US9575065B2Feb 21, 2017
Myeloperoxidase, a risk indicator for cardiovascular disease
CLEVELAND CLINIC FOUND0 citations51
US9522950B2Dec 20, 2016
Oxidant resistant apolipoprotein A-1 and mimetic peptides
CLEVELAND CLINIC FOUND0 citations51
US9435808B2Sep 6, 2016
Myeloperoxidase, a risk indicator for cardiovascular disease
CLEVELAND CLINIC FOUND0 citations51
US11835503B2Dec 5, 2023
TMA-formation inhibitor treatment for elevated TMA-containing compound diseases
CLEVELAND CLINIC FOUND0 citations50
US10064830B2Sep 4, 2018
Treatment and prevention of cardiovascular disease and thrombosis
CLEVELAND CLINIC FOUND1 citations49
CLEVELAND CLINIC FOUNDATION
10 patentsUS7459286B1Dec 2, 2008
Assessing the risk of a major adverse cardiac event in patients with chest pain
CLEVELAND CLINIC FOUNDATION16 citations92
US7771954B2Aug 10, 2010
Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents
CLEVELAND CLINIC FOUNDATION10 citations83
US7781219B2Aug 24, 2010
Risk markers for cardiovascular disease
CLEVELAND CLINIC FOUNDATION8 citations82
US9168233B2Oct 27, 2015
Treatment and prevention of cardiovascular disease and thrombosis
CLEVELAND CLINIC FOUNDATION11 citations81
US7780950B2Aug 24, 2010
Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents
CLEVELAND CLINIC FOUNDATION6 citations74
US8349581B2Jan 8, 2013
Assessing the risk of a major adverse cardiac event in patients with chest pain
CLEVELAND CLINIC FOUNDATION3 citations62
US7776563B2Aug 17, 2010
Methods for identifying agents for treating cardiovascular disease using inhibition of myeloperoxidase binding
CLEVELAND CLINIC FOUNDATION3 citations62
US7378396B2May 27, 2008
Therapeutic agents and methods for cardiovascular disease
CLEVELAND CLINIC FOUNDATION5 citations62
US9051393B2Jun 9, 2015
Oxidant resistant apolipoprotein A-1 and mimetic peptides
CLEVELAND CLINIC FOUNDATION2 citations61
US9005904B2Apr 14, 2015
Risk markers for cardiovascular disease
CLEVELAND CLINIC FOUNDATION1 citations60
HAZEN STANLEY L
9 patentsUS9423405B2Aug 23, 2016
Trimethylamine compounds as risk predictors of cardiovascular disease
HAZEN STANLEY L5 citations82
US8338110B2Dec 25, 2012
Risk markers for cardiovascular disease
HAZEN STANLEY L8 citations81
US10241093B2Mar 26, 2019
Trimethylamine-containing compounds for diagnosis and prediction of disease
HAZEN STANLEY L4 citations71
US9140703B2Sep 22, 2015
Combined F2-isoprostane and myeloperoxidase detection, a risk indicator for cardiovascular disease
HAZEN STANLEY L2 citations61
US8722344B2May 13, 2014
Risk markers for cardiovascular disease
HAZEN STANLEY L1 citations60
US9365889B2Jun 14, 2016
PON1 as a marker for heart failure
HAZEN STANLEY L0 citations52
US8628935B2Jan 14, 2014
PON1 as a marker for heart failure
HAZEN STANLEY L1 citations52
US9365888B2Jun 14, 2016
Assessing the risk of a major adverse cardiac event in patients with chest pain
HAZEN STANLEY L0 citations51
US9086425B2Jul 21, 2015
Carbamylated proteins and risk of cardiovascular disease
HAZEN STANLEY L0 citations40